$RRACF
Rigel Resource Acquisition Corp. Stock $rracf

$rracf Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000182912624007497 Filed on November 14, 2024

Income Statement

Concept	2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.406M
YoY Change	291.65%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$830.9K
YoY Change	-645.88%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$2.237M
YoY Change	981.94%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$211.5K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$70.68K
Receivables
Other Receivables
Total Short-Term Assets	$282.1K
YoY Change	44.7%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$82.13M
YoY Change	-69.2%
TOTAL ASSETS
Total Short-Term Assets	$282.1K
Total Long-Term Assets	$82.13M
Total Assets	$82.41M
YoY Change	-69.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.36M
YoY Change	205.61%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.36M
Total Long-Term Liabilities
Total Liabilities	$31.58M
YoY Change	24.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$31.48M
YoY Change	25.3%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$31.30M
YoY Change
Total Liabilities & Shareholders Equity	$82.41M
YoY Change	-69.12%

Cashflow Statement

Concept	2024 Q3
OPERATING ACTIVITIES
Net Income	-$2.237M
YoY Change	981.94%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Transition Report DocumentTransitionReport	false
	us-gaap	Operating Expenses OperatingExpenses	6129261	usd
	us-gaap	Operating Expenses OperatingExpenses	1016980	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity File Number EntityFileNumber	001-41022
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7 Bryant Park
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q3	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	30000	usd
	rrac	Warrant Offering Income WarrantOfferingIncome		usd
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1594226
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	90000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	926980	usd
	us-gaap	Interest Income Other InterestIncomeOther	10481777	usd
	rrac	Change In Fair Value Of Convertible Promissory Notes Related Parties ChangeInFairValueOfConvertiblePromissoryNotesRelatedParties	-72097	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-5177713	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5376161	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	4359181	usd
	rrac	Weighted Average Number Of Class Ordinary Shares Outstanding Basic And Diluted WeightedAverageNumberOfClassOrdinarySharesOutstandingBasicAndDiluted	29005501	shares
	rrac	Weighted Average Number Of Class B Ordinary Shares Outstanding Basic And Diluted WeightedAverageNumberOfClassBOrdinarySharesOutstandingBasicAndDiluted	7500000	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001860879
CY2024Q3	rrac	Deferred Underwriting Commission DeferredUnderwritingCommission		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2024Q3	rrac	Warrant Offering Income WarrantOfferingIncome		usd
CY2023Q3	rrac	Warrant Offering Income WarrantOfferingIncome		usd
CY2023Q1	rrac	Remeasurement Of Class Ordinary Shares RemeasurementOfClassOrdinaryShares		usd
CY2023Q2	rrac	Remeasurement Of Class Ordinary Shares RemeasurementOfClassOrdinaryShares		usd
CY2023Q3	rrac	Remeasurement Of Class Ordinary Shares RemeasurementOfClassOrdinaryShares		usd
	rrac	Warrant Offering Income WarrantOfferingIncome		usd
	rrac	Repayment Of Advances From Related Parties RepaymentOfAdvancesFromRelatedParties		usd
	rrac	Payment Of Offering Costs PaymentOfOfferingCosts		usd
	rrac	Proceeds Received In Excess Of Fair Value Of Promissory Note ProceedsReceivedInExcessOfFairValueOfPromissoryNote		usd
	rrac	Underwriting Fee Waiver UnderwritingFeeWaiver		usd
	dei	Entity Registrant Name EntityRegistrantName	Rigel Resource Acquisition Corp
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
	dei	Entity Address Address Line2 EntityAddressAddressLine2	1045 Avenue of the Americas
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Floor 25
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10018
	dei	City Area Code CityAreaCode	(646)
	dei	Local Phone Number LocalPhoneNumber	453-2672
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	211463	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70748	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	70680	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	55414	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	282143	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	126162	usd
CY2024Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	82128874	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	270667736	usd
CY2024Q3	us-gaap	Assets Assets	82411017	usd
CY2023Q4	us-gaap	Assets Assets	270793898	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4341520	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	706279	usd
CY2024Q3	rrac	Accrued Offering Costs AccruedOfferingCosts	378324	usd
CY2023Q4	rrac	Accrued Offering Costs AccruedOfferingCosts	378324	usd
CY2024Q3	us-gaap	Convertible Debt ConvertibleDebt	9635959	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	5556896	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14355803	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6641499	usd
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	17222405	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	8491527	usd
CY2023Q4	rrac	Deferred Underwriting Commission DeferredUnderwritingCommission	10500000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	31578208	usd
CY2023Q4	us-gaap	Liabilities Liabilities	25633026	usd
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	82128875	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	270667736	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	185931	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31482747	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25507614	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-31296066	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-25506864	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82411017	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	270793898	usd
CY2024Q3	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	30000	usd
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	90000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1375798	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	328944	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6039261	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	1405798	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	358944	usd
CY2024Q3	us-gaap	Interest Income Other InterestIncomeOther	1922882	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	3443700	usd
	us-gaap	Interest Income Other InterestIncomeOther	7855408	usd
	rrac	Warrant Offering Income WarrantOfferingIncome	680400	usd
CY2024Q3	rrac	Change In Fair Value Of Convertible Promissory Notes Related Parties ChangeInFairValueOfConvertiblePromissoryNotesRelatedParties	26652	usd
CY2023Q3	rrac	Change In Fair Value Of Convertible Promissory Notes Related Parties ChangeInFairValueOfConvertiblePromissoryNotesRelatedParties	-98889	usd
	rrac	Change In Fair Value Of Convertible Promissory Notes Related Parties ChangeInFairValueOfConvertiblePromissoryNotesRelatedParties	66170	usd
CY2024Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2727131	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-3390376	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-8730878	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-830901	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	152213	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-261240	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2236699	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-206731	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6390501	usd
CY2024Q3	rrac	Weighted Average Number Of Class Ordinary Shares Outstanding Basic And Diluted WeightedAverageNumberOfClassOrdinarySharesOutstandingBasicAndDiluted	14712221	shares
CY2023Q3	rrac	Weighted Average Number Of Class Ordinary Shares Outstanding Basic And Diluted WeightedAverageNumberOfClassOrdinarySharesOutstandingBasicAndDiluted	27016502	shares
	rrac	Weighted Average Number Of Class Ordinary Shares Outstanding Basic And Diluted WeightedAverageNumberOfClassOrdinarySharesOutstandingBasicAndDiluted	21260111	shares
CY2024Q3	rrac	Basic And Diluted Net Income Loss Per Share Of Class Ordinary Shares BasicAndDilutedNetIncomeLossPerShareOfClassOrdinaryShares	-0.10
CY2023Q3	rrac	Basic And Diluted Net Income Loss Per Share Of Class Ordinary Shares BasicAndDilutedNetIncomeLossPerShareOfClassOrdinaryShares	-0.01
	rrac	Basic And Diluted Net Income Loss Per Share Of Class Ordinary Shares BasicAndDilutedNetIncomeLossPerShareOfClassOrdinaryShares	-0.22
	rrac	Basic And Diluted Net Income Loss Per Share Of Class Ordinary Shares BasicAndDilutedNetIncomeLossPerShareOfClassOrdinaryShares	0.12
CY2024Q3	rrac	Weighted Average Number Of Class B Ordinary Shares Outstanding Basic And Diluted WeightedAverageNumberOfClassBOrdinarySharesOutstandingBasicAndDiluted	7500000	shares
CY2023Q3	rrac	Weighted Average Number Of Class B Ordinary Shares Outstanding Basic And Diluted WeightedAverageNumberOfClassBOrdinarySharesOutstandingBasicAndDiluted	7500000	shares
	rrac	Weighted Average Number Of Class B Ordinary Shares Outstanding Basic And Diluted WeightedAverageNumberOfClassBOrdinarySharesOutstandingBasicAndDiluted	7500000	shares
CY2024Q3	rrac	Basic And Diluted Net Income Loss Per Share Of Class B Ordinary Shares BasicAndDilutedNetIncomeLossPerShareOfClassBOrdinaryShares	-0.10
CY2023Q3	rrac	Basic And Diluted Net Income Loss Per Share Of Class B Ordinary Shares BasicAndDilutedNetIncomeLossPerShareOfClassBOrdinaryShares	-0.01
	rrac	Basic And Diluted Net Income Loss Per Share Of Class B Ordinary Shares BasicAndDilutedNetIncomeLossPerShareOfClassBOrdinaryShares	-0.22
	rrac	Basic And Diluted Net Income Loss Per Share Of Class B Ordinary Shares BasicAndDilutedNetIncomeLossPerShareOfClassBOrdinaryShares	0.12
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-25506864	usd
CY2024Q1	rrac	Fair Value In Excess Of Notes Payable Issued FairValueInExcessOfNotesPayableIssued	415368	usd
CY2024Q1	us-gaap	Accretion Expense AccretionExpense	4022086	usd
CY2024Q1	rrac	Waiver Of Deferred Underwriting Commission WaiverOfDeferredUnderwritingCommission	9819600	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-2906562	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-22200544	usd
CY2024Q2	rrac	Fair Value In Excess Of Notes Payable Issued FairValueInExcessOfNotesPayableIssued	415238	usd
CY2024Q2	us-gaap	Accretion Expense AccretionExpense	4010440	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-1247240	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-27042986	usd
CY2024Q3	rrac	Fair Value In Excess Of Notes Payable Issued FairValueInExcessOfNotesPayableIssued	293296	usd
CY2024Q3	us-gaap	Accretion Expense AccretionExpense	2309677	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-2236699	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-31296066	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-15989848	usd
CY2023Q1	rrac	Related Party Note Proceeds In Excess Of Fair Value RelatedPartyNoteProceedsInExcessOfFairValue	53009	usd
CY2023Q1	us-gaap	Accretion Expense AccretionExpense	3319794	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	1285224	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-17971409	usd
CY2023Q2	rrac	Related Party Note Proceeds In Excess Of Fair Value RelatedPartyNoteProceedsInExcessOfFairValue	639640	usd
CY2023Q2	us-gaap	Accretion Expense AccretionExpense	6718283	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	3280688	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-20769364	usd
CY2023Q3	rrac	Related Party Note Proceeds In Excess Of Fair Value RelatedPartyNoteProceedsInExcessOfFairValue	242125	usd
CY2023Q3	us-gaap	Accretion Expense AccretionExpense	4392087	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-206731	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-25126057	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6390501	usd
	us-gaap	Net Income Loss NetIncomeLoss	4359181	usd
	rrac	Investment Income Earned On Cash And Investments Held In Trust Account InvestmentIncomeEarnedOnCashAndInvestmentsHeldInTrustAccount	7855408	usd
	rrac	Investment Income Earned On Cash And Investments Held In Trust Account InvestmentIncomeEarnedOnCashAndInvestmentsHeldInTrustAccount	10481777	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-8730878	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-5177713	usd
	rrac	Change In Fair Value Of Convertible Promissory Note Related Parties ChangeInFairValueOfConvertiblePromissoryNoteRelatedParties	-66170	usd
	rrac	Change In Fair Value Of Convertible Promissory Note Related Parties ChangeInFairValueOfConvertiblePromissoryNoteRelatedParties	72097	usd
	rrac	Warrant Offering Income WarrantOfferingIncome	680400	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	15266	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-412006	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	3635242	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	285463	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2509285	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-319511	usd
	rrac	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount	2486795	usd
	rrac	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount	3948367	usd
	rrac	Cash Withdrawn From Trust Account For Redemptions CashWithdrawnFromTrustAccountForRedemptions	198881065	usd
	rrac	Cash Withdrawn From Trust Account For Redemptions CashWithdrawnFromTrustAccountForRedemptions	58279780	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	196394270	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	54331413	usd
	rrac	Repayment Of Advances From Related Parties RepaymentOfAdvancesFromRelatedParties	99722	usd
	rrac	Payments Made In Relation To Redemptions Of Class Ordinary Shares PaymentsMadeInRelationToRedemptionsOfClassOrdinaryShares	198881065	usd
	rrac	Payments Made In Relation To Redemptions Of Class Ordinary Shares PaymentsMadeInRelationToRedemptionsOfClassOrdinaryShares	58279780	usd
	rrac	Proceeds From Convertible Promissory Notes Related Parties ProceedsFromConvertiblePromissoryNotesRelatedParties	5136795	usd
	rrac	Proceeds From Convertible Promissory Notes Related Parties ProceedsFromConvertiblePromissoryNotesRelatedParties	4398367	usd
	rrac	Payment Of Offering Costs PaymentOfOfferingCosts	15000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-193744270	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-53996135	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	140715	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	15767	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70748	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109595	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	211463	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125362	usd
	rrac	Current Period Accretion To Redemption Value CurrentPeriodAccretionToRedemptionValue	10342203	usd
	rrac	Current Period Accretion To Redemption Value CurrentPeriodAccretionToRedemptionValue	14430164	usd
	rrac	Proceeds Received In Excess Of Fair Value Of Promissory Note ProceedsReceivedInExcessOfFairValueOfPromissoryNote	1123902	usd
	rrac	Underwriting Fee Waiver UnderwritingFeeWaiver	-9819600	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zW9jQFL8zOF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.75in"><b>NOTE 1.</b></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><b><span id="xdx_82C_zxBfTwHB97y9">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND GOING CONCERN</span></b></td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rigel Resource Acquisition Corp (the “Company”) was incorporated in the Cayman Islands on April 6, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company formed RRAC NewCo which was incorporated in the Cayman Islands with Limited Liability as an Exempted Company, with effect from February 8, 2024. RRAC NewCo changed its name to Aurous Resources on May 27, 2024 as certified by the Registrar of the Companies. The Company owns no material assets and does not operate any business. Aurous Resources is a wholly owned subsidiary of the Company and was formed for the purpose of becoming the ultimate parent company of Blyvoor Gold Resources Proprietary Limited, a South African private limited liability company (“Aurous Gold”) and Blyvoor Gold Operations Proprietary Limited, a South African private limited liability company (“Gauta Tailings”) following the transactions contemplated in the Business Combination Agreement dated March 11, 2024 entered into by and among Rigel, Aurous Gold, Gauta Tailings, Aurous Resources, and RRAC Merger Sub, a Cayman Islands exempted company and wholly owned subsidiary of Aurous Resources (“Merger Sub”). Merger Sub was incorporated on February 28, 2024 to facilitate the consummation of the Business Combination Agreement. There are no other activities in the subsidiary of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Business Combination Agreement, and as per the terms and subject to the conditions therein, among other things, (i) Rigel will merge with and into the Merger Sub (the ‘Merger’), with Merger Sub being the surviving company, and (ii) Aurous Resources will acquire all of the issued and outstanding equity interests of Aurous Gold and Gauta Tailings (the ‘Share Exchange’). Following the Merger and the Share Exchange, each of Aurous Gold, Gauta Tailings and Merger Sub will be a wholly owned subsidiary of Aurous Resources, and Aurous Resources will become a publicly traded company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All activity for the period from April 6, 2021 (inception) through September 30, 2024 relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is described below, and the search for a target company. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 9, 2021, the Company consummated the Initial Public Offering of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211101__20211109__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Stock issued during period shares issued in initial public offering">27,500,000 </span>units (“Units” and, with respect to the ordinary shares included in the Units which were offered, the “Public Shares”), generating gross proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211101__20211109__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Gross proceeds from issuance of initial public offering">275,000,000</span>, which is described in Note 3.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Simultaneously with the closing of the Initial Public Offering, the Company consummated the private sale (the “Private Placement”) of an aggregate of <span id="xdx_907_ecustom--ClassOfWarrantsAndRightsIssuedDuringThePeriod_c20211101__20211109__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember_pdd" title="Class of warrants and rights issued during the period">14,000,000</span> warrants (the “Private Placement Warrants”) <span id="xdx_909_ecustom--ClassOfWarrantsAndRightsIssuedDuringThePeriod_c20211101__20211109__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SposorMember_pdd" title="Class of warrants and rights issued during the period">11,300,000 </span>to Rigel Resource Acquisition Holding LLC (the “Sponsor”), <span id="xdx_909_ecustom--ClassOfWarrantsAndRightsIssuedDuringThePeriod_c20211101__20211109__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NathanaelAbebeMember_pdd" title="Class of warrants and rights issued during the period">100,000 </span>to Nathanael Abebe, <span id="xdx_903_ecustom--ClassOfWarrantsAndRightsIssuedDuringThePeriod_c20211101__20211109__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChristineCoignardMember_pdd" title="Class of warrants and rights issued during the period">35,000 </span>to Christine Coignard, <span id="xdx_90B_ecustom--ClassOfWarrantsAndRightsIssuedDuringThePeriod_c20211101__20211109__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KelvinDushniskyMember_pdd" title="Class of warrants and rights issued during the period">25,000 </span>to Kelvin Dushnisky, <span id="xdx_906_ecustom--ClassOfWarrantsAndRightsIssuedDuringThePeriod_c20211101__20211109__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LPeterOHaganMember_pdd" title="Class of warrants and rights issued during the period">200,000 </span>to L. Peter O’Hagan and <span id="xdx_907_ecustom--ClassOfWarrantsAndRightsIssuedDuringThePeriod_c20211101__20211109__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OrionMineFinanceGPMember_pdd" title="Class of warrants and rights issued during the period">2,340,000</span> to Orion Mine Finance GP III LP (“Orion GP”) at a purchase price of $<span id="xdx_90B_ecustom--ClassOfWarrantsAndRightsIssuedPricePerWarrant_c20211101__20211109__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember_pdd" title="Class of warrants and rights issued, price per warrant">1.00 </span>per Private Placement Warrant, generating gross proceeds to the Company in the amount of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20211101__20211109__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember_pp0p0" title="Gross proceeds from private placement issue">14,000,000</span>, which is described in Note 4.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 9, 2021, the underwriter purchased an additional <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211101__20211109__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pdd" title="Stock issued during period shares issued in initial public offering">2,500,000 </span>Units pursuant to a partial exercise of the over-allotment option. The Units were sold at an offering price of $10.00 per Unit, generating additional gross proceeds to the Company of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211101__20211109__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pp0p0" title="Gross proceeds from issuance of initial public offering">25,000,000</span>. Since the underwriter did not exercise the remainder of the over-allotment option, the Sponsor forfeited <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20211101__20211109__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_pdd" title="Shares subject to forfeiture">406,250 </span>Founder Shares upon the expiration of the over-allotment option in December 2021. The Sponsor transferred <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20211101__20211109_pdd" title="Shares subject to forfeiture">1,170,000 </span>Founder Shares to Orion GP (an affiliate of the Sponsor) at the time of the initial closing, in connection with the purchase of private placement warrants by Orion GP.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of November 9, 2021, transaction costs amounted to $<span id="xdx_902_ecustom--TransactionCostsInConnectionWithInitialPublicOffering_c20211101__20211109__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Transaction costs">17,585,547 </span>consisting of $<span id="xdx_904_ecustom--UnderwritingFees_c20211101__20211109__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Underwriting fees">6,000,000 </span>of underwriting fees in cash, $<span id="xdx_902_ecustom--DeferredUnderwritingFees_c20211109__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Deferred underwriting fees">10,500,000</span> of deferred underwriting fees payable (which are held in a trust account with Continental Stock Transfer & Trust Company acting as trustee (the “Trust Account”)) and $<span id="xdx_906_ecustom--CostsRelatedToInitialPublicOffering_c20211101__20211109__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Costs related to Initial Public Offering">1,085,547 </span>of costs related to the Initial Public Offering. Cash of $<span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_c20240930_zFQoF05BfBc" title="Cash">70,748 </span>was held outside of the Trust Account on December 31, 2023 and was available for working capital purposes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the closing of the Initial Public Offering on November 9, 2021, an amount of $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211101__20211109__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Sale of stock">306,000,000</span> ($<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_c20211109__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Share Price">10.20 </span>per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement was placed in Trust Account which may be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the Trust Account, as described below. On May 8, 2023, the Sponsor deposited an aggregate of $3,000,000 into the Company’s trust account for the Company’s public shareholders, representing $0.10 per public share, which enabled the Company to extend the period of time it has to consummate its initial Business Combination by three months, from May 9, 2023 to August 9, 2023. On August 10, 2023, the Company instructed Continental Stock Transfer & Trust Company, the trustee with respect to the Trust Account, to liquidate the U.S. government treasury obligations or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in an interest bearing demand deposit account at a bank until the earlier of the consummation of the Company’s initial Business Combination or the liquidation of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company’s extraordinary general meeting held on August 7, 2023 (the “2023 Special Meeting”), the Company’s shareholders approved a special resolution to amend the Company’s amended and restated memorandum and articles of association (the “Charter”) to extend the date by which the Company must either consummate an initial Business Combination or (i) cease its operations, except for the purpose of winding up if it fails to complete an initial Business Combination and (ii) redeem all of the Class A ordinary shares (the “Public Shares”) included as part of the units sold in the Company’s initial public offering, from August 9, 2023 to August 9, 2024 (the “2023 Extension Amendment”). In connection with the 2023 Extension Amendment, <span id="xdx_900_ecustom--RedemptionOfClassOrdinarySharesDescription_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedemptionofClassAOrdinarySharesMember_z6k720WTSG4g" title="Redemption of Class A Ordinary Shares description">the holders of 5,429,967 Class A Ordinary Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.73 per share, for an aggregate redemption amount of $58,279,780, leaving approximately $263,710,000 in the Company’s trust account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 28, 2023, the Company amended and restated: (i) that the First Extension Loan and (ii) the Second Extension Loan (together with the First Extension Loan, the “Amended and Restated Extension Loans”) to add Orion GP, an affiliate of the Sponsor, as a payee (together with the Sponsor, the “Payees”). The Amended and Restated Extension Loans will be repayable by the Company to the Payees on a pro rata basis based on the amount of the principal balance each Payee has advanced under the Amended and Restated Extension Loans. The Amended and Restated Extension Loans do not otherwise materially modify the terms of the First Extension Loan and the Second Extension Loan and are effective as of May 8, 2023 and August 9, 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company’s extraordinary general meeting held on August 9, 2024 (the “2024 Special Meeting”), the Company’s shareholders approved a special resolution to amend the Company’s Charter to extend the date by which the Company must either (1) consummate an initial Business Combination or (2) (i) cease its operations, except for the purpose of winding up if it fails to complete an initial Business Combination, and (ii) redeem all of the Public Shares, from August 9, 2024 to May 9, 2025 (the “2024 Extension Amendment”). In connection with the 2024 Extension Amendment, the holders of 17,440,475 Class A Ordinary Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.40 per share, for an aggregate redemption amount of $<span id="xdx_908_ecustom--RedemptionAmount_iI_c20240930_zfIYHDb30DZe" title="Redemption amount">198,881,064</span>, leaving approximately $<span id="xdx_903_ecustom--TrustAccount_iI_c20240930_zIR9WiYDMy22" title="Trust account">81,301,345</span> in the Company’s trust account. See Note 10 for more information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Convertible Promissory Note dated as of August 9, 2023 (the “Second Extension Loan”), the Sponsor has agreed that it will contribute to the Company as a loan (each loan being referred to herein as a “Second Extension Loan Contribution”) the lesser of <span id="xdx_901_ecustom--ConvertiblePromissoryNoteDescription_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SecondExtensionLoanMember_zWwwVvjYt1P4" title="Convertible promissory note description">(A) $0.03 for each Public Share that was not redeemed in connection with the 2023 Special Meeting and (B) $350,000, for each month (or a pro rata portion thereof if less than a month) until the earlier of (i) the date of the extraordinary general meeting held in connection with the shareholder vote to approve an initial Business Combination and (ii) August 9, 2024. The maximum aggregate amount of all Second Extension Loan Contributions will not exceed $4,200,000, and the Second Extension Loan Contributions will be deposited into the Company’s trust account. Up to $1,500,000 of the Second Extension Loan Contributions can be settled in whole warrants to purchase Class A Ordinary Shares of the Company at a conversion price equal to $1.00 per warrant. The Second Extension Loan Contributions will not bear any interest and will be repayable by the Company to the Sponsor upon the earlier of the date by which the Company must complete an initial Business Combination and the consummation of the Company’s initial Business Combination. The maturity date of the Second Extension Loan may be accelerated upon the occurrence of an Event of Default (as defined therein). Any outstanding principal under the Second Extension Loan may be prepaid at any time by the Company, at its election and without penalty. On August 9, 2023, August 31, 2023, September 29, 2023, October 31, 2023, November 30, 2023, December 29, 2023, January 31, 2024, February 29, 2024, March 29, 2024, April 30, 2024, May 30, 2024, June 26, 2024 and July 31, 2024 the Sponsor made contributions of approximately $248,387, $350,000, $350,000, $350,000, $350,000, $350,000, $350,000, $350,000, $350,000, $350,000, $350,000, $350,000 and $101,613 respectively, to the Trust Account under the Second Extension Loan. See Note 5 for more information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Convertible Promissory Note dated as of August 12, 2024 (the “Third Extension Loan”), the Sponsor and Orion GP have agreed that they will contribute to the Company as a loan (each loan being referred to herein as a “Third Extension Loan Contribution”) of $0.02 for each Public Share that was not redeemed in connection with the 2024 Special Meeting for each month (or a pro rata portion thereof if less than a month) until the earlier of <span id="xdx_900_ecustom--ConvertiblePromissoryNoteDescription_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdExtensionLoanMember_zWJLs9mFf4Sa" title="Convertible promissory note description">(i) the date of the extraordinary general meeting held in connection with the shareholder vote to approve an initial Business Combination and (ii) May 9, 2025. The Third Extension Loan Contributions will be deposited into the Company’s trust account. Loans under the Third Extension Loan can be settled in whole warrants to purchase Class A Ordinary Shares of the Company at a conversion price equal to $1.00 per warrant. The Third Extension Loan will not bear any interest and will be repayable by the Company upon the earlier of the date by which the Company must complete an initial Business Combination and the consummation of the Company’s initial Business Combination. The maturity date of the Third Extension Loan may be accelerated upon the occurrence of an Event of Default (as defined therein). Any outstanding principal under the Third Extension Loan may be prepaid at any time by the Company, at its election and without penalty. On August 13, 2024, September 9, 2024, October 8, 2024 and November 8, 2024 the Sponsor and Orion GP made aggregate contributions of approximately $142,591, $142,591, $142,591 and $142,591, respectively, to the Trust Account under the Third Extension Loan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the value of the net assets held in the Trust Account (as defined above) (excluding the deferred underwriting commissions). The Company will only complete a Business Combination if the post transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will provide the holders of the outstanding Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares either (i) in connection with a general meeting called to approve the Business Combination or (ii) by means of a tender offer in connection with the Business Combination. The decision as to whether the Company will seek shareholder approval for a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.20 per Public Share, and such amount will be increased in the case of extensions of the Company’s time to consummate our initial Business Combination, as described herein, plus any pro rata interest then in the Trust Account). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. The Public Shares subject to redemption will be recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Accounting Standards Codification (“ASC”) Topic 480 “<i>Distinguishing Liabilities from Equity</i>.”</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Company seeks shareholder approval of the Business Combination, the Company will proceed with a Business Combination only if the Company receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company, or such other vote as required by law or stock exchange rule. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (the “SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares without the Company’s prior written consent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holders of the Founder Shares have agreed (a) to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the Company’s initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii) with respect to any other provision relating to shareholders’ rights or pre-initial Business Combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Company has not completed a Business Combination by May 9, 2025 (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holders of the Founder Shares have agreed to waive the rights to liquidating distributions from the Trust Account with respect to the Founder Shares they will receive if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor or any of its respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriter has agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.20, or higher in case extensions of the time period to complete the Company’s initial Business Combination have been effectuated).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (1) $10.20 per Public Share following the closing of the Initial Public Offering, $10.30 per public share after 18 months from the closing of the Initial Public Offering, or $10.40 per public share after 21 months from the closing of the Initial Public Offering, as applicable; and (2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.20 per Public Share, due to reductions in the value of trust assets. This liability will not apply to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and as to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Going Concern Considerations</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2024, the Company had cash of $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_c20240930_pp0p0" title="Cash">211,463</span> and working capital deficit of $<span id="xdx_901_ecustom--WorkingCapitalDeficit_iI_c20240930_z9v97feWsFPk" title="Working capital deficit">14,073,660</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. In addition, the Company currently has less than 12 months from the date these financial statements were issued to complete a Business Combination transaction. If the Company is unsuccessful in consummating an initial Business Combination by May 9, 2025, per the mandatory liquidation requirement, the Company must cease all operations, redeem the Public Shares and thereafter liquidate and dissolve. In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, <i>“Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,”</i> the Company does not have adequate liquidity to sustain operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. There is no assurance that the Company’s plans to raise capital or to consummate a Business Combination will be successful or successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management is currently evaluating the impact of the invasion by Russia of Ukraine and any further escalation of hostilities related thereto, terrorist attacks, natural disasters or significant outbreaks of infectious diseases on the industry and has concluded that while it is reasonably possible that such events could have a negative effect on the Company’s financial position, results of its operations and/or search for and consummation of a business combination with a target company, the specific impacts are not readily determinable as of the date of these financial statements. These financial statements do not include any adjustments that might result from the outcome of these uncertainties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	1170000	shares
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	70748	usd
CY2024Q3	rrac	Redemption Amount RedemptionAmount	198881064	usd
CY2024Q3	rrac	Trust Account TrustAccount	81301345	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	211463	usd
CY2024Q3	rrac	Working Capital Deficit WorkingCapitalDeficit	14073660	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zUKazRi3nT83" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zui6W90EjfQ8">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. The Company’s significant estimates and assumptions include the fair value of the related parties convertible notes and the change in fair value of the derivative liabilities. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2024Q3	us-gaap	Assets Held In Trust AssetsHeldInTrust	82100000	usd
CY2023Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	270700000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	82100000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	270700000	usd
	rrac	Warrant Exercisable WarrantExercisable	15000000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_znlFUdCdowuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zuwdwQRdndP4">Concentration of Credit Risk</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the Federal depository insurance coverage of $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20240930_zohXAKDZH4Bj" title="Federal Depository Insurance Corporation">250,000</span>. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_847_eus-gaap--DerivativesReportingOfDerivativeActivity_zHDfjP74NDO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zWu3GkB9xJ0j">Derivative Financial Instruments</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “<i>Derivatives and Hedging</i>.” The Company’s derivative instruments are recorded at fair value as of the closing date of the Initial Public Offering (November 9, 2021) and re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the public warrants, the Private Placement Warrants and the Forward Purchase Agreement are derivative instruments. As the public warrants, the Private Placement Warrants and the Forward Purchase Agreement meet the definition of a derivative, the public warrants, the Private Placement Warrants and Forward Purchase Agreement are measured at fair value at issuance and at each reporting date in accordance with ASC 820, <i>Fair Value Measurement</i>, with changes in fair value recognized in the statements of operations in the period of change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	10000	usd
CY2024Q1	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	30000	usd
CY2023Q1	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	30000	usd
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	90000	usd
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	90000	usd
CY2023Q4	rrac	Working Capital Loans WorkingCapitalLoans	600000	usd
CY2024Q2	rrac	Promissory Note Agreement PromissoryNoteAgreement	the Company entered into a Promissory Note (the “May 2024 Working Capital Loan”) with the Sponsor. Pursuant to the May 2024 Working Capital Loan, the Sponsor has agreed to loan to the Company up to $1,000,000 to be used for working capital purposes. The loans will not bear any interest, and will be repayable by the Company to the Sponsor upon the earlier of the date by which the Company must complete an initial Business Combination pursuant to its amended Charter (as amended from time to time) and the consummation of the Company’s initial Business Combination. On May 30, 2024, June 25, 2024 and July 31, 2024, the Company borrowed $250,000, $500,000 and $250,000 under the May 2024 Working Capital Loan, respectively. As of September 30, 2024 and December 31, 2023, there was $1,000,000 and $0 outstanding under the May 2024 Working Capital Loan, respectively, and is included in convertible promissory notes - related parties on the accompanying balance sheets.
CY2024Q3	rrac	Accrued Legal Fees AccruedLegalFees	378300	usd
CY2023Q4	rrac	Accrued Legal Fees AccruedLegalFees	378300	usd
CY2024Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3249100	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	113400	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2600000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	0	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.10
CY2024Q3	rrac	Redemption Price Per Share RedemptionPricePerShare	10.00
	rrac	Class Of Warrants Or Rights Issued During The Period ClassOfWarrantsOrRightsIssuedDuringThePeriod	29000000	shares
CY2024Q3	us-gaap	Extended Product Warranty Accrual Current ExtendedProductWarrantyAccrualCurrent	37584000	usd
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	26858364	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	14048423	usd
CY2023Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	14048423	usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1850000	usd
CY2024Q1	rrac	Proceed In Excess Of Fair Value ProceedInExcessOfFairValue	-415368	usd
CY2024Q1	rrac	Change In Fair Value ChangeInFairValue	4308994	usd
CY2024Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	19792049	usd
CY2024Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1900000	usd
CY2024Q2	rrac	Proceed In Excess Of Fair Value ProceedInExcessOfFairValue	-415238	usd
CY2024Q2	rrac	Change In Fair Value ChangeInFairValue	1734271	usd
CY2024Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	23011082	usd
CY2024Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1386795	usd
CY2024Q3	rrac	Proceed In Excess Of Fair Value ProceedInExcessOfFairValue	-293296	usd
CY2024Q3	rrac	Change In Fair Value ChangeInFairValue	2753783	usd
CY2024Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	26858364	usd

Files In Submission

Name	View Source	Status
0001829126-24-007497-index-headers.html	Edgar Link	pending
0001829126-24-007497-index.html	Edgar Link	pending
0001829126-24-007497.txt	Edgar Link	pending
0001829126-24-007497-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rigelresources_10q.htm	Edgar Link	pending
rigelresources_ex31-1.htm	Edgar Link	pending
rigelresources_ex31-2.htm	Edgar Link	pending
rigelresources_ex32-1.htm	Edgar Link	pending
rigelresources_ex32-2.htm	Edgar Link	pending
rrac-20240930.xsd	Edgar Link	pending
rrac-20240930_lab.xml	Edgar Link	unprocessable
rigelresources_10q_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
rrac-20240930_pre.xml	Edgar Link	unprocessable
rrac-20240930_cal.xml	Edgar Link	unprocessable
rrac-20240930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RRACF
Rigel Resource Acquisition Corp. Stock $rracf

2024 Q3 Form 10-Q Financial Statement

#000182912624007497 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RRACF Rigel Resource Acquisition Corp. Stock $rracf

2024 Q3 Form 10-Q Financial Statement

#000182912624007497 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RRACF
Rigel Resource Acquisition Corp. Stock $rracf